Grifols, a producer of plasma-derived medicines and diagnostic solutions, acquired 10 percent of Bloodbuy (BloodSolutions, LLC), a cloud-based marketplace that facilitates buying and selling of blood components in the United States, the company announced in a press release.
Bloodbuy’s proprietary technology platform and computer-based algorithms enable regional blood-collection centers to expand their customer base across the United States, while providing hospitals and other healthcare providers with greater access to vital blood components.
Bloodbuy’s platform allows participating healthcare providers to supplement their blood component needs on both a recurring and on-demand basis, while providing blood-collection centers with the ability to distribute their lifesaving products more broadly. The platform also reduces waste of biological products while improving profitability.
“COVID-19 has created unprecedented challenges for our blood supply, both with respect to supply and demand shocks related to social distancing, suspension of elective procedures, and other necessary public health interventions,” said Chris Godfrey, Founder and CEO of Bloodbuy. “These externalities have had profoundly negative effects on blood product availability and utilization from region-to-region.”
